Sensus Healthcare Reports Second Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Second Quarter Revenues of $9.2 million compare with $4.5 million in the prior-year quarter, a djusted EBITDA (

Healthcare Reports Second Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Second Quarter

call begins at 4:30 p.m. Eastern time today

RATON, Fla. (August 8, 2024) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective,

non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial

results for the three and six months ended June 30, 2024.

from the second quarter of 2024 and recent weeks include the following:

sales momentum continued in the second quarter of 2024 with very strong revenue growth over the 2023 second quarter, along with positive

net income and positive Adjusted EBITDA," said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "Our

Fair Deal Agreement is off to a strong start with 15 agreements signed since

our launch at the American Academy of Dermatology meeting in March. We expect to be generating recurring revenue from these SRT-100 Vision

(IG-SRT) systems in 2025. This program addresses customer needs to deploy capital to other areas of their business, especially during

challenging macroeconomic conditions. Given the growing utilization of SRT to treat non-melanoma skin cancer and keloids, and the interest

we have generated to date, we expect this model to contribute to our growth for years to come.

efforts, in particular in Asia, are progressing well. During the second quarter we shipped two units to China and one to Taiwan, and

are working to establish distribution in South Korea and Japan. Our goal is to make SRT the standard of care for treating non-melanoma

skin cancer and keloids, and we are energized by this tremendous global opportunity," Mr. Sardano concluded.

Quarter Financial Results

for the second quarter of 2024 were $9.2 million, compared with $4.5 million for the second quarter of 2023, an increase of $4.7 million,

or 104%. The increase was primarily driven by a higher number of SRT systems sold to a large customer.

of sales was $3.8 million for the second quarter of 2024, compared with $1.9 million for the prior-year quarter. The increase was primarily

related to a higher number of units sold in the 2024 quarter and was fairly consistent as a percentage of revenues.

profit was $5.4 million for the second quarter of 2024, or 58.7% of revenues, compared with $2.6 million, or 57.9% of revenues, for the

second quarter of 2023. The increase was primarily driven by the higher number of units sold in the 2024 quarter.

and marketing expense was $1.0 million for the second quarter of 2024, compared with $1.6 million for the prior-year quarter. The decrease

was primarily attributable to a decline in marketing agency expense, lower headcount and a decrease in tradeshow costs.

and administrative expense was $1.6 million for the second quarter of 2024, compared with $1.3 million for the second quarter of 2023.

The increase was primarily due to higher professional fees and compensation.

and development expense was $0.9 million for the second quarter of 2024, compared with $0.8 million for the second quarter of 2023. The

increase was primarily due to expenses related to a project to develop a drug delivery system for aesthetic use.

income of $0.2 million for the second quarter of 2024 was mostly related to interest income, and was unchanged from the prior-year quarter.

income for the second quarter of 2024 was $1.6 million, or $0.10 per diluted share, compared with a net loss of $0.4 million, or $0.02

per share, for the second quarter of 2023.

EBITDA for the second quarter of 2024 was $2.1 million, compared with negative $1.0 million for the second quarter of 2023. Adjusted

EBITDA, a non-GAAP financial measure, is defined as earnings before interest, taxes, depreciation, amortization and stock-compensation

expense. Please see below for a reconciliation between GAAP and non-GAAP financial measures, and the reasons these non-GAAP financial

measures are provided.

and cash equivalents were $19.0 million as of June 30, 2024, compared with $23.1 million as of December 31, 2023. The Company had no

outstanding borrowings under its revolving line of credit. Accounts receivable were $18.3 million as of June 30, 2024, compared with

$10.6 million as of December 31, 2023. Prepaid inventory was $3.3 million, compared with $3.0 million, and inventories were $12.8 million,

compared with $11.9 million, reflecting continued preparations for higher expected unit sales and placements for the second half of 2024.

Month Financial Results

for the first half of 2024 were $20.0 million, compared with $8.0 million for the first half of 2023, an increase of $12.0 million, or

152%. The increase was primarily driven by a higher number of units sold to a large customer.

of sales was $7.8 million for the first half of 2024, compared with $3.7 million for the first half of 2023. The increase was primarily

related to higher sales in the 2024 period.

profit was $12.1 million, or 60.7% of revenues, for the first half of 2024, compared with $4.2 million, or 53.4% of revenues, for the

first half of 2023. The increase was primarily driven by a higher number of units sold in the 2024 period.

and marketing expense was $2.3 million for the first half of 2024, compared with $3.7 million for the first half of 2023. The decrease

was primarily attributable to a decline in marketing agency expense, lower headcount and a decrease in tradeshow costs.

and administrative expense was $3.2 million for the first half of 2024, compared with $2.7 million for the first half of 2023. The increase

was primarily due to higher professional fees and compensation.

and development expense was $1.8 million for the first half of 2024, compared with $1.9 million for the first half of 2023. The decrease

was primarily due to a net reduction of expenses related to a project to develop a drug delivery system for aesthetic use.

income of $0.4 million and $0.5 million for the first half of 2024 and 2023, respectively, relates primarily to interest income.

income for the first half of 2024 was $3.9 million, or $0.24 per diluted share, compared with a net loss of $2.3 million, or $0.14 per

share, for the first half of 2023.

EBITDA for the first half of 2024 was $5.1 million, compared with negative $3.7 million for the first half of 2023.

of Non-GAAP Financial Information

press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally

accepted in the United States (GAAP). Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis

of the Company's performance. Adjusted EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed

as a substitute for operating results determined in accordance with GAAP. Management believes the presentation of Adjusted EBITDA, which

excludes the impact of interest, income taxes, depreciation, amortization and stock-compensation expense, provides useful supplemental

information that is essential to a proper understanding of the financial results of Sensus Healthcare. Non-GAAP financial measures are

not formally defined by GAAP, and other entities may use calculation methods that differ from those used by Sensus Healthcare. As a complement

to GAAP financial measures, management believes that Adjusted EBITDA assists investors who follow the practice of some investment analysts

who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. A reconciliation

of the GAAP net loss to Adjusted EBITDA is provided in the schedule below.

SENSUS HEALTHCARE, INC.

GAAP TO NON-GAAP RECONCILIATION

Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will

discuss these financial results, provide a business update and answer questions. To

access the conference call, dial 844-481-2811 (U.S. and Canada Toll Free) or 412-317-0676 (International). The call will be webcast

live and can be accessed at this link, or in the Investors section of the Company's website at

www.sensushealthcare.com.

the conclusion of the conference call, a replay will be available until September 8, 2024 and can be accessed by dialing 877-344-7529

(U.S. Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International), using replay code 2699495. An archived webcast of

the call will also be available in the Investors section of the Company's website.

Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging

its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective,

patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions

that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.

press release includes statements that are, or may be deemed, forward-looking statements.'' In some cases,

these statements can be identified by the use of forward-looking terminology such as "believes," "estimates,"

"anticipates," "expects," "plans," "intends," "may," "could,"

"might," "will," "should," "approximately," "potential" or negative or other

variations of those terms or comparable terminology, although not all forward-looking statements contain these words.

statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry,

and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to

a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with

the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods.

Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking

statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the

development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release,

as a result of the following factors, among others: our ability to maintain profitability; our ability to sell the number of SRT units

we anticipate for the balance of 2024; the possibility that inflationary pressures continue to impact our sales; the level and availability

of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers

to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our

ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign